In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled on the determined monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 might be given as "include-on" therapy. In Section C, https://abbv-744-brd4-inhibition79024.blogdosaga.com/31898518/brd4-targeted-therapy-abbv-744-clinical-data-no-further-a-mystery